Top Markets
#1 Black Phoenix Black Phoenix +826.34%
#2 pipedog pipedog +28.14%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.27%
#4 SAFEcoin SAFEcoin +25.29%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +23.78%
#6 Bless Bless +22.81%
#7 PondCoin PondCoin +19.97%
#8 Beam Beam +19.73%
#9 Magma Finance Magma Finance +19.65%
#10 Asteroid Shiba Asteroid Shiba +17.65%
Coin of the day
Black Phoenix Black Phoenix
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Pozycja w akcjach #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Cena akcji
$32.88
Kapitalizacja rynkowa
$2.08B
Zmiana (1 dzień)
-0.48%
Zmiana (1 rok)
96.77%
Kraj
US
Handel Zenas BioPharma, Inc. (ZBIO)

Kategoria

Healthcare
Zyski dla Zenas BioPharma, Inc. (ZBIO)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Zenas BioPharma, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Zenas BioPharma, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH